Addressing the need for change 2021
IRD Invest is a virtual investor conference series hosted by IR Department to showcase emerging companies, and to provide an additional value-add for our investor and client networks.
We are all part of a new era. After reaching a low point in mid-2020, the investment landscape has changed dramatically. Companies, like investment markets, are adapting. We want to illustrate how our clients deal with change and provide fresh solutions to assist mitigate the effects of change.
Our third IRD Invest virtual investor conference ran over two days in late September 2021. We heard from a range of ASX listed companies that are innovating by addressing evolving consumer trends and patient needs.
Companies that presented:
Wednesday 22 September: Addressing evolving consumer needs
John Kelly, Founder, Managing Director & CEO and Will Souter, Chief Financial Officer, Atomo Diagnostics (ASX: AT1)
Atomo is an Australian medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market. Atomo’s patented devices simplify testing procedures and enhance usability for professional users and untrained self-testers. Atomo has supply agreements in place for tests targeting infectious diseases including HIV, COVID-19, and viral vs bacterial differentiation.
Dr Chris Hart, CEO Oventus Medical Limited (ASX: OVN)
Oventus is a Brisbane-based medical device company that is commercialising a unique treatment platform for obstructive sleep apnea (OSA) and snoring. The Company has a collaborative Sleep Physician/ Dental strategy that streamlines patients’ access to treatment. The Oventus lab model incorporates digital technology via intra oral scanning to achieve operational efficiencies, accuracy and ultimately patient outcomes.
Michael Eidel, Group Chief Executive Officer and Managing Director, Openpay Group Ltd (ASX: OPY)
Openpay is a fast-growing and highly differentiated player in the global 'Buy now pay later' (BNPL) payment solutions market. The Company’s strong platform enables it to deliver the most flexible plans in the market with durations of 2–24 months and values of up to $20,000.
Oliver Horn, Executive Director and Global CEO, Elixinol Wellness Limited (ASX: EXL)
Elixinol Wellness Limited is a global leader in the hemp industry, innovating, marketing and selling hemp derived nutraceutical, cosmetic and food products.
Martin Filz, Chief Executive Officer & Melinda Sheppard Chief Operating Officer and CFO, Pureprofile Ltd (ASX: PPL)
Pureprofile connects brands with empowered customers across the world by finding, understanding, and engaging them through direct-to-consumer technology platforms. The Pureprofile group is a global leader in data and insights, programmatic media and performance media. Pureprofile delivers next-generation marketing solutions for more than 500 brands, publishers and research groups worldwide.
Thursday 23 September: Addressing new needs in patient care
Dr James Garner, CEO & Executive Director, Kazia Therapeutics Limited (ASX: KZA)
Kazia is an Australian oncology company developing innovative, high-impact drugs for cancer. Its lead program is paxalisib, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults.
Michelle Gallaher, Chief Executive Officer, Opyl Limited (ASX: OPL)
Opyl is an Australian company that provides leading biopharma and health organisations access to emerging AI-assisted technologies and real-world data insights to understand and improve healthcare design, development, and delivery.
Brian Leedman, Non-Executive Director, Neurotech International Limited (ASX: NTI)
Neurotech International Limited is a medical device and solutions company conducting clinical studies to assess the neuro-protective, anti-inflammatory and neuro-modulatory activities of our proprietary NTI/Dolce cannabis strains.
Dr Tim Oldham, CEO and Managing Director, AdAlta Limited (ASX: 1AD)
AdAlta Limited is a clinical stage drug development company headquartered in Melbourne, Australia. The Company is using its proprietary i-body technology platform to solve challenging drug targeting problems and generate a promising new class of single domain antibody protein therapeutics.
Phillip R Lynch, CEO & Managing Director and Dr Daniel Tillett, Chief Scientific Officer & Executive Director, Race Oncology (ASX: RAC)
Race Oncology is an ASX listed precision oncology company with a Phase 2/3 cancer drug called Zantrene® (bisantrene dihydrochloride). Zantrene® is a potent inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein. Overexpression of FTO has been shown to be the genetic driver of a diverse range of cancers.
September 23, 2021
Watch the presentation